Newlink Genetics Corp (NLNK) 34.51 $NLNK
Market Movers - Biotech Stocks -- NewLink Genetics, Biogen Idec, United Therapeutics, Dynavax Technologies, and Amarin
PR Newswire - Wed Oct 29, 7:40AM CDT
Investor-Edge has initiated coverage on the following equities: NewLink Genetics Corporation (NASDAQ: NLNK), Biogen Idec Inc. (NASDAQ: BIIB), United Therapeutics Corporation (NASDAQ: UTHR), Dynavax Technologies Corporation (NASDAQ: DVAX), and Amarin Corporation PLC (NASDAQ: AMRN). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Tuesday, October 28, 2014, the NASDAQ Composite ended at 4,564.29, up 1.75%, the Dow Jones Industrial Average advanced 1.12%, to finish the day at 17,005.75, and the S&P 500 closed at 1,985.05, up 1.19%. The gains were broad based as all the sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 760.91, up 0.74%, with the index also advancing 6.21% in the previous three months. Register for your complimentary reports on these five stocks at:
DVAX: 1.68 (unch), BIIB: 315.06 (-2.97), AMRN: 0.90 (-0.02), UTHR: 130.60 (+0.11), NLNK: 34.51 (-0.39)
Time Magazine Warns Against Investing In Certain "Ebola Stocks"
ACCESSWIRE - Tue Oct 28, 8:22AM CDT
LOS ANGELES, CA / ACCESSWIRE / October 28, 2014 / Time Magazine is today warning investors that while developmental stage pharmas like Inovio Pharmaceuticals (NASDAQ:INO , NewLink Genetics Corp. (NASDAQ:NLNK), Tekmira Pharmaceuticals (NASDAQ:TKMR) and Sarepta Therapeutics (NASDAQ:SRPT) have all generated significant interest among stock market investors lately, there are good reasons to shy away from buying into experimental Ebola treatment therapies. But how can this be?
INO: 11.20 (-0.18), MRK: 56.20 (+0.35), PFE: 29.49 (+0.40), SRPT: 15.19 (+0.07), NLNK: 34.51 (-0.39), TKMR: 16.87 (-1.46), GSK: 45.08 (-0.02), NVS: 91.31 (-1.04)
Why I Won't Buy Ebola Stocks
George Budwell, The Motley Fool - Motley Fool - Mon Oct 27, 9:28AM CDT
Source: Science Photo Library The recent outbreak of the deadly Ebola virus in Western Africa is now the worst on record, and public health officials are desperately searching for new ways to combat this serious threat to global health. As a...
INO: 11.20 (-0.18), SRPT: 15.19 (+0.07), NLNK: 34.51 (-0.39), TKMR: 16.87 (-1.46), GSK: 45.08 (-0.02)
NewLink Genetics to Host Its Third Quarter 2014 Earnings Results Conference Call on November 6, 2014
GlobeNewswire - Mon Oct 27, 7:00AM CDT
NewLink Genetics Corporation (Nasdaq:NLNK) will release its third quarter 2014 financial results on Thursday, November 6, 2014. The company has scheduled a conference call for 8:30 AM ET the same day to discuss the results and to give an update on clinical and business development activities.
NLNK: 34.51 (-0.39)
NewLink Genetics Corporation (NLNK) in Focus: Stock Soars 15.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Oct 23, 8:18AM CDT
NewLink Genetics Corporation (NLNK) was a big mover last session, as the company saw its shares rise by over 15% on the day.
HALO: 9.31 (-0.05), NLNK: 34.51 (-0.39), ILMN: 188.88 (-1.77), EXAS: 24.66 (-0.34)
3 Biotech Stocks With Humongous Short Interest
Todd Campbell, The Motley Fool - Motley Fool - Wed Oct 22, 8:05AM CDT
Buying when everyone else is scared may sound like a fantastic way to buy great companies at bargain-basement prices, but it can be tricky to figure out when there's enough fear to justify buying, especially in hit-and-miss industries...
EBS: 21.91 (-0.03), NLNK: 34.51 (-0.39), TEVA: 54.49 (-0.31), AMRI: 22.90 (+0.17)
'Fast Money' Recap: Yahoo! The Market Continues to Rally
at The Street - Wed Oct 22, 4:00AM CDT
The trading panel discussed whether it's time to buy or sell Yahoo! stock and Carl Icahn weighs in on Apple and the fixed income market.
KO: 40.96 (+0.40), MNST: 98.65 (+1.20), DIS: 89.53 (-0.40), YHOO: 45.43 (-0.44), RIG: 29.90 (+0.01), DIA: 169.40 (-0.26), MDY: 254.46 (-0.29), NLNK: 34.51 (-0.39), LOCO: 36.71 (+0.29), MCD: 92.73 (+0.13), AAPL: 107.34 (+0.60), QID: 42.92 (+0.28), BABA: 98.31 (-1.37)
NewLink-Roche Ink Deal for Oncology Candidate Development - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 21, 5:05PM CDT
NewLink Genetics Corporation (NLNK) has signed an exclusive license agreement with Roche for the development of its oncology candidate, NLG919.
MDVN: 99.55 (-1.63), HALO: 9.31 (-0.05), NLNK: 34.51 (-0.39)
Vaccines, Medical Oxygen, and Helping the Ebola Crisis
ACCESSWIRE - Tue Oct 21, 12:47PM CDT
Whitefish, MT / ACCESSWIRE / October 21, 2014 / The Ebola outbreak has caused 4,555 deaths with 9,216 confirmed cases in Guinea, Liberia, Nigeria, Senegal, Sierra Leone, Spain, and the United States, according to World Health Organization data up to October 14, 2014. While Nigeria has since been pronounced disease-free, the epidemic continues to affect many other African countries that have been unable to contain its spread.
JNJ: 105.56 (+0.77), NLNK: 34.51 (-0.39), GSK: 45.08 (-0.02)
Will NewLink (NLNK) Continue to Surge Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Oct 21, 9:02AM CDT
Will NewLink (NLNK) Continue to Surge Higher?
NLNK: 34.51 (-0.39)
NewLink Genetics Corp. (NLNK) Jumps: Stock Rises 7.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Oct 21, 7:51AM CDT
NewLink Genetics Corporation (NLNK) was a big mover last session, as its shares rose over 7% on the day.
MACK: 9.19 (-0.16), HALO: 9.31 (-0.05), NLNK: 34.51 (-0.39), ILMN: 188.88 (-1.77)
'Fast Money' Recap: How Much Higher Can Apple Shares Go?
at The Street - Tue Oct 21, 4:00AM CDT
The trading panel discussed the tech company's earnings and whether to buy Pandora, CSX or Chipotle Mexican Grill
HTZ: 22.36 (-0.07), PNRA: 165.42 (-5.58), P: 19.23 (-0.51), IBM: 163.46 (-0.14), SUNE: 18.75 (-0.31), FB: 75.86 (-4.91), CMG: 639.86 (-5.99), NLNK: 34.51 (-0.39), MCD: 92.73 (+0.13), CSX: 35.40 (+0.11), AAPL: 107.34 (+0.60), FINL: 25.74 (+0.04)
Global Potential Analysis of Ebola Drug and Vaccines Market 2014-2020: Leading Companies are Tekmira, BioCryst, Serepata Therapeutics, NewLink Genetics and Mapp Biopharmaceutical
M2 - Tue Oct 21, 3:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/84gs7d/global_potential) has announced the addition of the "Global Potential Analysis of Ebola drug and Vaccines Market (Pipeline analysis, Drugs, Vaccines, and Geography) through 2020" report to their offering. Tekmira Pharmaceuticals, BioCryst Pharmaceutical Inc., Serepata Therapeutics, NewLink Genetics and Mapp Biopharmaceutical are some of the leading companies focusing on research activities to develop efficacious medicine for EVD. Additionally, the governments in the developed countries have also taken formidable steps to support the research activities for the development of EVD therapeutics by providing funding and floating favorable policies. As an example, Tekmira Pharmaceuticals has received fast-track designation from U.S. food and drug administration for their anti-ebola therapeutic TKM-ebola. In 2012, Sarepta Therapeutics had also received fast track designation for AVI-7537, a lead drug candidate for EVD. Both these companies are developing their anti-ebola products under the contract of the U.S. department of defense (DoD). Ebola therapeutics and vaccines market is segmented on the basis of geography into North America, Europe, Asia-pacific and LAMEA. EVD is rampant in LAMEA regions, specifically in African countries. This is a positive sign for pharmaceutical companies, portraying a highly lucrative market in the future. Earlier, US government did not have any regulations for EVD therapeutics due to negligible incidences of this disease in developed economies. However, preference of African people to migrate to developed economies rather than developing economies has cautioned the governments in the developed economies, leading to formulate regulations in order to curb the spread of this disease. Summary As an example, government of the United States, through the FDA, has granted Fast Track designation to the Tekmira's TKM Ebola drug and has funded $140 million through the Department of defense, United States, for R&D on EVD. According to AMR analyst, Roshan Deshmukh, The prime focus of the companies is to commercialize the drugs and vaccines for EVD disease. The government authorities across the developed regions are extending support for the commercialization of these drugs by provid ing funds and floating favorable policies. Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Market Overview - Market Definition and Scope - Key Findings - Key market player positioning - Ebola Virus Key Facts - Amend for anti-Ebola disease drugs in United States - Guidance on Air Medical Transport for Patients with Ebola Virus Disease - Fast Track designation to Anti-E bola drugs research from the U.S. government - ZMMP Drug: An Orphan solution for E-bola viral disease - Ethical Dilemmas from therapeutics - Tekmira Pharma received boost to ebola R&D through FDA fundings - Clinical Trials - Market Dynamics Chapter 4 Forecast Scenario Analysis Of Ebola Vaccines, 2013-2020, ($Million) - Moderate growth scenario - Rapid growth scenario - Diminishing growth scenario Chapter 5 Global Pipeline And Market Potential Analysis Of E-Bola Therapeutic Vaccines Market By Geography, 2013 - 2020 Chapter 6 Company Profiles - Tekmira Pharmaceuticals - BioCryst Pharmaceutical Inc. - Serepata Therapeutics - NewLink Genetics Corp. - Mapp Biopharmaceutical For more information visit http://www.researchandmarkets.com/research/84..._potential
SRPT: 15.19 (+0.07), NLNK: 34.51 (-0.39), TKMR: 16.87 (-1.46)
Competitor Analysis: Ebola Virus Vaccines and Therapeutics Report 2014 Featuring Over 30 Insitutions
M2 - Tue Oct 21, 3:09AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nkwpbp/competitor) has announced the addition of the "Competitor Analysis: Ebola Virus Vaccines and Therapeutics" report to their offering. The present Competitive Intelligence Report about prophylaxis and therapy of Ebola virus infections provides a competitor evaluation in the field of new molecules for prevention or treatment of Ebola virus infections as of October 2014. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report. The report includes a compilation of currently active projects in research and development of therapeutic antibodies, immunoglobulins, RNA, proteins, vaccines and small molecules for prevention and treatment of Ebola virus infections. In addition, the report lists company-specific R&D pipelines of Ebola virus vaccines and therapeutics. Competitor projects are listed in a tabular format providing information on: - Drug Codes - Target / Mechanism of Action - Class of Compound - Company - Product Category - Indication - R&D Stage Key Topics Covered: 1. Ebola Virus Vaccines 2. Ebola Virus Therapeutics 3. Corporate Ebola Virus Vaccines & Therapeutics R&D Pipeline Companies Mentioned - Bavarian Nordic - Biocryst Pharmaceuticals - Chimerix - Defyrus - Fab'entech - Fujifilm Holdings - GlaxoSmithKline (Wellcome Trust; Okairos) - Hemispherx - Immunovaccine - Inovio Pharmaceuticals - Ivanov Institute (of Russian Health Ministry) - Johnson & Johnson (Crucell) - LeafBio - Mapp Biopharmaceuticals - MediVector - Mitsubishi Tanabe Pharma (Medicago) - Nanoviricides - National Institutes of Health (NIH) / National Institute of Allergy and Infectious Diseases (NIAID) - NewLink Genetics (BioProtection Systems) - Novartis - Pentamer Pharmaceuticals - Profectus Biosciences - Public Health Agency of Canada - Sarepta Therapeutics - Tekmira - Thomas Jefferson University - United States Army Medical Research Institute for Infectious Diseases (USAMRIID) - US Department of Defense's Defense Threat Reduction Agency (DTRA) - Vaxart - Walter Reed Army Institute of Research (WRAIR) For more information visit http://www.researchandmarkets.com/research/nkwpbp/competitor
JNJ: 105.56 (+0.77), INO: 11.20 (-0.18), SRPT: 15.19 (+0.07), NLNK: 34.51 (-0.39), GSK: 45.08 (-0.02), NVS: 91.31 (-1.04)
Why NewLink Genetics (NLNK) Stock Is Soaring Today
at The Street - Mon Oct 20, 9:41AM CDT
The company said it entered into an agreement with Roche Holding (RHHBY) to develop NewLink's cancer immunotherapy.
NLNK: 34.51 (-0.39)
Stocks Open Quietly Mixed; Hasbro, NewLink, Akorn Rising
at Investor's Business Daily - Mon Oct 20, 9:37AM CDT
Stocks sagged at Monday's open but quickly recovered and were narrowly mixed. The Nasdaq led, up 0.4% with an assist from Apple 's (AAPL) 1% gain. The S&P 500 added 0.1%. The Dow Jones industrial average was 0.5% in the red. Trading was quiet, with...
HAS: 57.62 (-0.11), AMD: 2.77 (+0.05), IBM: 163.46 (-0.14), AKRX: 43.14 (-0.40), NLNK: 34.51 (-0.39), AAPL: 107.34 (+0.60)
NewLink Genetics Announces Exclusive Worldwide Licensing Agreement for Development of NLG919, an IDO Inhibitor in Phase 1, and Research Collaboration for the Discovery of Next Generation IDO/TDO Inhibitors
eTeligis - Mon Oct 20, 7:21AM CDT
AMES, IA, United States, via ETELIGIS INC., 10/20/2014 - - NewLink Genetics Corporation (NASDAQ: NLNK), a biopharmaceutical company focused on discovering, developing, and commercializing novel immunotherapeutics to improve treatment options for patients with cancer, announced today that they have entered into an exclusive worldwide license agreement with Genentech, a member of the Roche Group, for the development of NLG919, NewLink's IDO pathway inhibitor. The parties also entered into a research collaboration for the discovery of next generation IDO/TDO compounds.
NLNK: 34.51 (-0.39)
Healthcare Stocks in Focus on Ebola Fears - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 17, 1:34PM CDT
The WHO has declared the Ebola epidemic a public health emergency of international concern.
AGN: 186.77 (+4.17), INO: 11.20 (-0.18), BCRX: 11.93 (-0.27), SRPT: 15.19 (+0.07), NLNK: 34.51 (-0.39), TKMR: 16.87 (-1.46), GSK: 45.08 (-0.02)
Market Movers - Biotech Stocks -- NewLink Genetics, Biogen Idec, United Therapeutics, Dynavax Technologies, and Amarin
PR Newswire - Wed Oct 29, 7:40AM CDT
Investor-Edge has initiated coverage on the following equities: NewLink Genetics Corporation (NASDAQ: NLNK), Biogen Idec Inc. (NASDAQ: BIIB), United Therapeutics Corporation (NASDAQ: UTHR), Dynavax Technologies Corporation (NASDAQ: DVAX), and Amarin Corporation PLC (NASDAQ: AMRN). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Tuesday, October 28, 2014, the NASDAQ Composite ended at 4,564.29, up 1.75%, the Dow Jones Industrial Average advanced 1.12%, to finish the day at 17,005.75, and the S&P 500 closed at 1,985.05, up 1.19%. The gains were broad based as all the sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 760.91, up 0.74%, with the index also advancing 6.21% in the previous three months. Register for your complimentary reports on these five stocks at:
DVAX: 1.68 (unch), BIIB: 315.06 (-2.97), AMRN: 0.90 (-0.02), UTHR: 130.60 (+0.11), NLNK: 34.51 (-0.39)
Time Magazine Warns Against Investing In Certain "Ebola Stocks"
ACCESSWIRE - Tue Oct 28, 8:22AM CDT
LOS ANGELES, CA / ACCESSWIRE / October 28, 2014 / Time Magazine is today warning investors that while developmental stage pharmas like Inovio Pharmaceuticals (NASDAQ:INO , NewLink Genetics Corp. (NASDAQ:NLNK), Tekmira Pharmaceuticals (NASDAQ:TKMR) and Sarepta Therapeutics (NASDAQ:SRPT) have all generated significant interest among stock market investors lately, there are good reasons to shy away from buying into experimental Ebola treatment therapies. But how can this be?
INO: 11.20 (-0.18), MRK: 56.20 (+0.35), PFE: 29.49 (+0.40), SRPT: 15.19 (+0.07), NLNK: 34.51 (-0.39), TKMR: 16.87 (-1.46), GSK: 45.08 (-0.02), NVS: 91.31 (-1.04)
Why I Won't Buy Ebola Stocks
George Budwell, The Motley Fool - Motley Fool - Mon Oct 27, 9:28AM CDT
Source: Science Photo Library The recent outbreak of the deadly Ebola virus in Western Africa is now the worst on record, and public health officials are desperately searching for new ways to combat this serious threat to global health. As a...
INO: 11.20 (-0.18), SRPT: 15.19 (+0.07), NLNK: 34.51 (-0.39), TKMR: 16.87 (-1.46), GSK: 45.08 (-0.02)
NewLink Genetics to Host Its Third Quarter 2014 Earnings Results Conference Call on November 6, 2014
GlobeNewswire - Mon Oct 27, 7:00AM CDT
NewLink Genetics Corporation (Nasdaq:NLNK) will release its third quarter 2014 financial results on Thursday, November 6, 2014. The company has scheduled a conference call for 8:30 AM ET the same day to discuss the results and to give an update on clinical and business development activities.
NLNK: 34.51 (-0.39)
NewLink Genetics Corporation (NLNK) in Focus: Stock Soars 15.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Oct 23, 8:18AM CDT
NewLink Genetics Corporation (NLNK) was a big mover last session, as the company saw its shares rise by over 15% on the day.
HALO: 9.31 (-0.05), NLNK: 34.51 (-0.39), ILMN: 188.88 (-1.77), EXAS: 24.66 (-0.34)
3 Biotech Stocks With Humongous Short Interest
Todd Campbell, The Motley Fool - Motley Fool - Wed Oct 22, 8:05AM CDT
Buying when everyone else is scared may sound like a fantastic way to buy great companies at bargain-basement prices, but it can be tricky to figure out when there's enough fear to justify buying, especially in hit-and-miss industries...
EBS: 21.91 (-0.03), NLNK: 34.51 (-0.39), TEVA: 54.49 (-0.31), AMRI: 22.90 (+0.17)
'Fast Money' Recap: Yahoo! The Market Continues to Rally
at The Street - Wed Oct 22, 4:00AM CDT
The trading panel discussed whether it's time to buy or sell Yahoo! stock and Carl Icahn weighs in on Apple and the fixed income market.
KO: 40.96 (+0.40), MNST: 98.65 (+1.20), DIS: 89.53 (-0.40), YHOO: 45.43 (-0.44), RIG: 29.90 (+0.01), DIA: 169.40 (-0.26), MDY: 254.46 (-0.29), NLNK: 34.51 (-0.39), LOCO: 36.71 (+0.29), MCD: 92.73 (+0.13), AAPL: 107.34 (+0.60), QID: 42.92 (+0.28), BABA: 98.31 (-1.37)
NewLink-Roche Ink Deal for Oncology Candidate Development - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 21, 5:05PM CDT
NewLink Genetics Corporation (NLNK) has signed an exclusive license agreement with Roche for the development of its oncology candidate, NLG919.
MDVN: 99.55 (-1.63), HALO: 9.31 (-0.05), NLNK: 34.51 (-0.39)
Vaccines, Medical Oxygen, and Helping the Ebola Crisis
ACCESSWIRE - Tue Oct 21, 12:47PM CDT
Whitefish, MT / ACCESSWIRE / October 21, 2014 / The Ebola outbreak has caused 4,555 deaths with 9,216 confirmed cases in Guinea, Liberia, Nigeria, Senegal, Sierra Leone, Spain, and the United States, according to World Health Organization data up to October 14, 2014. While Nigeria has since been pronounced disease-free, the epidemic continues to affect many other African countries that have been unable to contain its spread.
JNJ: 105.56 (+0.77), NLNK: 34.51 (-0.39), GSK: 45.08 (-0.02)
Will NewLink (NLNK) Continue to Surge Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Oct 21, 9:02AM CDT
Will NewLink (NLNK) Continue to Surge Higher?
NLNK: 34.51 (-0.39)
NewLink Genetics Corp. (NLNK) Jumps: Stock Rises 7.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Oct 21, 7:51AM CDT
NewLink Genetics Corporation (NLNK) was a big mover last session, as its shares rose over 7% on the day.
MACK: 9.19 (-0.16), HALO: 9.31 (-0.05), NLNK: 34.51 (-0.39), ILMN: 188.88 (-1.77)
'Fast Money' Recap: How Much Higher Can Apple Shares Go?
at The Street - Tue Oct 21, 4:00AM CDT
The trading panel discussed the tech company's earnings and whether to buy Pandora, CSX or Chipotle Mexican Grill
HTZ: 22.36 (-0.07), PNRA: 165.42 (-5.58), P: 19.23 (-0.51), IBM: 163.46 (-0.14), SUNE: 18.75 (-0.31), FB: 75.86 (-4.91), CMG: 639.86 (-5.99), NLNK: 34.51 (-0.39), MCD: 92.73 (+0.13), CSX: 35.40 (+0.11), AAPL: 107.34 (+0.60), FINL: 25.74 (+0.04)
Global Potential Analysis of Ebola Drug and Vaccines Market 2014-2020: Leading Companies are Tekmira, BioCryst, Serepata Therapeutics, NewLink Genetics and Mapp Biopharmaceutical
M2 - Tue Oct 21, 3:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/84gs7d/global_potential) has announced the addition of the "Global Potential Analysis of Ebola drug and Vaccines Market (Pipeline analysis, Drugs, Vaccines, and Geography) through 2020" report to their offering. Tekmira Pharmaceuticals, BioCryst Pharmaceutical Inc., Serepata Therapeutics, NewLink Genetics and Mapp Biopharmaceutical are some of the leading companies focusing on research activities to develop efficacious medicine for EVD. Additionally, the governments in the developed countries have also taken formidable steps to support the research activities for the development of EVD therapeutics by providing funding and floating favorable policies. As an example, Tekmira Pharmaceuticals has received fast-track designation from U.S. food and drug administration for their anti-ebola therapeutic TKM-ebola. In 2012, Sarepta Therapeutics had also received fast track designation for AVI-7537, a lead drug candidate for EVD. Both these companies are developing their anti-ebola products under the contract of the U.S. department of defense (DoD). Ebola therapeutics and vaccines market is segmented on the basis of geography into North America, Europe, Asia-pacific and LAMEA. EVD is rampant in LAMEA regions, specifically in African countries. This is a positive sign for pharmaceutical companies, portraying a highly lucrative market in the future. Earlier, US government did not have any regulations for EVD therapeutics due to negligible incidences of this disease in developed economies. However, preference of African people to migrate to developed economies rather than developing economies has cautioned the governments in the developed economies, leading to formulate regulations in order to curb the spread of this disease. Summary As an example, government of the United States, through the FDA, has granted Fast Track designation to the Tekmira's TKM Ebola drug and has funded $140 million through the Department of defense, United States, for R&D on EVD. According to AMR analyst, Roshan Deshmukh, The prime focus of the companies is to commercialize the drugs and vaccines for EVD disease. The government authorities across the developed regions are extending support for the commercialization of these drugs by provid ing funds and floating favorable policies. Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Market Overview - Market Definition and Scope - Key Findings - Key market player positioning - Ebola Virus Key Facts - Amend for anti-Ebola disease drugs in United States - Guidance on Air Medical Transport for Patients with Ebola Virus Disease - Fast Track designation to Anti-E bola drugs research from the U.S. government - ZMMP Drug: An Orphan solution for E-bola viral disease - Ethical Dilemmas from therapeutics - Tekmira Pharma received boost to ebola R&D through FDA fundings - Clinical Trials - Market Dynamics Chapter 4 Forecast Scenario Analysis Of Ebola Vaccines, 2013-2020, ($Million) - Moderate growth scenario - Rapid growth scenario - Diminishing growth scenario Chapter 5 Global Pipeline And Market Potential Analysis Of E-Bola Therapeutic Vaccines Market By Geography, 2013 - 2020 Chapter 6 Company Profiles - Tekmira Pharmaceuticals - BioCryst Pharmaceutical Inc. - Serepata Therapeutics - NewLink Genetics Corp. - Mapp Biopharmaceutical For more information visit http://www.researchandmarkets.com/research/84..._potential
SRPT: 15.19 (+0.07), NLNK: 34.51 (-0.39), TKMR: 16.87 (-1.46)
Competitor Analysis: Ebola Virus Vaccines and Therapeutics Report 2014 Featuring Over 30 Insitutions
M2 - Tue Oct 21, 3:09AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nkwpbp/competitor) has announced the addition of the "Competitor Analysis: Ebola Virus Vaccines and Therapeutics" report to their offering. The present Competitive Intelligence Report about prophylaxis and therapy of Ebola virus infections provides a competitor evaluation in the field of new molecules for prevention or treatment of Ebola virus infections as of October 2014. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report. The report includes a compilation of currently active projects in research and development of therapeutic antibodies, immunoglobulins, RNA, proteins, vaccines and small molecules for prevention and treatment of Ebola virus infections. In addition, the report lists company-specific R&D pipelines of Ebola virus vaccines and therapeutics. Competitor projects are listed in a tabular format providing information on: - Drug Codes - Target / Mechanism of Action - Class of Compound - Company - Product Category - Indication - R&D Stage Key Topics Covered: 1. Ebola Virus Vaccines 2. Ebola Virus Therapeutics 3. Corporate Ebola Virus Vaccines & Therapeutics R&D Pipeline Companies Mentioned - Bavarian Nordic - Biocryst Pharmaceuticals - Chimerix - Defyrus - Fab'entech - Fujifilm Holdings - GlaxoSmithKline (Wellcome Trust; Okairos) - Hemispherx - Immunovaccine - Inovio Pharmaceuticals - Ivanov Institute (of Russian Health Ministry) - Johnson & Johnson (Crucell) - LeafBio - Mapp Biopharmaceuticals - MediVector - Mitsubishi Tanabe Pharma (Medicago) - Nanoviricides - National Institutes of Health (NIH) / National Institute of Allergy and Infectious Diseases (NIAID) - NewLink Genetics (BioProtection Systems) - Novartis - Pentamer Pharmaceuticals - Profectus Biosciences - Public Health Agency of Canada - Sarepta Therapeutics - Tekmira - Thomas Jefferson University - United States Army Medical Research Institute for Infectious Diseases (USAMRIID) - US Department of Defense's Defense Threat Reduction Agency (DTRA) - Vaxart - Walter Reed Army Institute of Research (WRAIR) For more information visit http://www.researchandmarkets.com/research/nkwpbp/competitor
JNJ: 105.56 (+0.77), INO: 11.20 (-0.18), SRPT: 15.19 (+0.07), NLNK: 34.51 (-0.39), GSK: 45.08 (-0.02), NVS: 91.31 (-1.04)
Why NewLink Genetics (NLNK) Stock Is Soaring Today
at The Street - Mon Oct 20, 9:41AM CDT
The company said it entered into an agreement with Roche Holding (RHHBY) to develop NewLink's cancer immunotherapy.
NLNK: 34.51 (-0.39)
Stocks Open Quietly Mixed; Hasbro, NewLink, Akorn Rising
at Investor's Business Daily - Mon Oct 20, 9:37AM CDT
Stocks sagged at Monday's open but quickly recovered and were narrowly mixed. The Nasdaq led, up 0.4% with an assist from Apple 's (AAPL) 1% gain. The S&P 500 added 0.1%. The Dow Jones industrial average was 0.5% in the red. Trading was quiet, with...
HAS: 57.62 (-0.11), AMD: 2.77 (+0.05), IBM: 163.46 (-0.14), AKRX: 43.14 (-0.40), NLNK: 34.51 (-0.39), AAPL: 107.34 (+0.60)
NewLink Genetics Announces Exclusive Worldwide Licensing Agreement for Development of NLG919, an IDO Inhibitor in Phase 1, and Research Collaboration for the Discovery of Next Generation IDO/TDO Inhibitors
eTeligis - Mon Oct 20, 7:21AM CDT
AMES, IA, United States, via ETELIGIS INC., 10/20/2014 - - NewLink Genetics Corporation (NASDAQ: NLNK), a biopharmaceutical company focused on discovering, developing, and commercializing novel immunotherapeutics to improve treatment options for patients with cancer, announced today that they have entered into an exclusive worldwide license agreement with Genentech, a member of the Roche Group, for the development of NLG919, NewLink's IDO pathway inhibitor. The parties also entered into a research collaboration for the discovery of next generation IDO/TDO compounds.
NLNK: 34.51 (-0.39)
Healthcare Stocks in Focus on Ebola Fears - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 17, 1:34PM CDT
The WHO has declared the Ebola epidemic a public health emergency of international concern.
AGN: 186.77 (+4.17), INO: 11.20 (-0.18), BCRX: 11.93 (-0.27), SRPT: 15.19 (+0.07), NLNK: 34.51 (-0.39), TKMR: 16.87 (-1.46), GSK: 45.08 (-0.02)
